Member Info for Kjn2

Has anyone spoken to Investor relations recently? Or sent a message to the Chairman/Board? Think it’s time imo that they do some work to support the share price here. Taking a LTIP/options and paying a small fortune to Rothschild and zero outcome so far. Embarrassing.

Yes, also because capex drops. But the owners want to crystallise value so if there isn’t a sale they could split the company in an opco.

Yes, some would argue though that the stock has never really reflected the underlying value. That’s why they launched the strategic review I guess. If there isn’t a good deal, imo the large holders could swap entire board and management team. Same team and different results don’t work after all these years clearly imo.

You are mixing up things: with 50%+1 you are stuck with minority shareholders. You cannot delist Spire.

You need 75% for a successful takeover and delisting.

No, wrong. A scheme requires 75%. Impossible without Mediclinic agreeing.

Not really, because I think as it was reported that Mediclinic and their new owners want to sell. Doubt they sell to Tosca and other investors for 220p or so.

The Board didn’t extend and negotiate with Bridgepoint. What do you think the large holders will do if the Board don’t deliver a better outcome asap? Imo bye bye board seats and maybe we see the CEO getting fired.

Yes, imo nice short squeeze coming. Another Pusu, especially with a strategic and the stock will rip back to 180-190.

Pusu only relates to publicly named parties.

Eg, if Sky report another party another Pusu will be triggered.

There is no deadline to the process itself, wouldn’t make sense anyway.

I think there may be strategic buyers left in the process. Hence no Pusu for them so far. But now time for them to make a move, enough time and money spent by the Board so far, think many holders could agree.

Back to topic:

I expect another Pusu, any potential bidders left had enough time for due diligence. I think: another Sky article, Pusu, bid and takeover done. 240p is my guess, could be a strategic or LP.

Look at Bloomberg, Tosca haven’t sold down and stop spreading misinformation on here. Clueless.

Lol, Tosca own 18%. Embarrassing what you post on here. Don’t even know the most basic facts.

Back to the topic as plenty of posts that add zero value here.

Whats next in the process?:

- strategic buyer: possible, but can’t have material antitrust risk. The Board needs to get things done asap.

- PE buyer: possible, returns work for them until 260p, but depends if Tosca/Mediclinic agree to that

- another Pusu? I can imagine the press is digging for names in the process. Could trigger another Pusu.

- MBO?: don’t forget Tosca/Harwood have private capital vehicles. If they partner with a LP/fund they could take Spire private for cheap, ie 220p or so, but I doubt Mediclinic would agree

Overall risk/reward is obviously much better for longs now, good short squeeze potential as well. The Board needs to put in some night shifts now, otherwise imo hard to imagine any of them seeing another term.

We could see another PUSU soon potentially, the Board will work hard to get a deal done and there isn’t a lack of potential buyers. Good buying opportunity today imo.

People misunderstand PUSU: it ONLY relates to publicly named parties in the process. There could be 5 other bidders in the process now. Today’s news is positive.

Great news: The Board of Spire Healthcare remains in discussions with other parties in relation to a potential sale of the Company.

The Board of Spire Healthcare remains in discussions with other parties in relation to a potential sale

of the Company. There can be no certainty that any offer will be made for the Company nor as to the

terms of any offer, if made.

The Board and Management are also continuing to actively evaluate other appropriate actions to drive

long-term, sustainable shareholder value.

The Board will make a further announcement on this matter in due course as appropriate.

The Company remains in an "Offer Period" as defined in the Code. Accordingly, the dealing disclosure

requirements listed below will continue to apply.

https://investors.spirehealthcare.com/media/if5oj3vg/mar-26-project-tulip-announcement_vfinal.pdf

And let’s call them Rothschild

Harwood isn’t allowed to name other bidders, and I doubt he would want to have non public material information. Time that the Board deliver.